Abstract In Caucasians, a histidine for glutamine substitution (Gln->His) at residue 360 in apolipoprotein (apo)
S everal epidemiological and clinical studies have
revealed an inverse correlation between low plasma concentrations of high-density lipoprotein (HDL) cholesterol and the risk of myocardial infarction (reviewed in Reference 1). The reverse cholesterol transport model is the one most widely used to explain the protective role of HDL in atherogenesis. In this model, HDL mediates efflux of excess cholesterol from peripheral cells into plasma as well as the esterification of cholesterol in plasma by lecithin: cholesterol acyltransferase (LCAT). From HDL, cholesterol esters are subsequently delivered to the liver by several mechanisms. In humans the most important pathway apparently involves the exchange of cholesterol esters for triglycerides from low-density lipoprotein (LDL) and very low-density li-had significantly higher mean plasma activity levels of lecithin:cholesterol acyltransferase (LCAT) (/><.01). Multivariate analysis of the effects of age, diabetes mellitus, intake of lipid-lowering drugs, body mass index, smoking, and apo A-IV polymorphism revealed that the apo A-IV polymorphism contributed 1%, 3% to 4%, 6% to 7%, and 5% to 18% of the variation in serum concentrations and plasma activities of Lp A-I, apo A-IV, LCAT, and CETP, respectively. In men, univariate and multivariate regression analyses revealed significant interrelationships between concentrations and activities of HDL cholesterol, Lp A-I, apo A-IV, LCAT, and CETP. We conclude that the 360: Gin/His apo A-IV polymorphism influences HDL metabolism via apo A-IV concentration and/or plasma activities of LCAT and CETP. However, these effects appear to be strongly modulated by other factors, including gender, and do not contribute importantly to cardiovascular risk. Family and twin studies suggest that low HDL cholesterol levels are partially hereditary and have estimated the influence of genes to be 35% to 50%. 56 It has therefore been hypothesized that genetic defects that interfere with either the regular structure of HDL or the processes that generate and remove HDL are disadvantageous to those who carry such defects. To date, however, only a few structural defects in apolipoprotein (apo) A-I, LCAT, and CETP have been shown to regulate plasma HDL cholesterol concentrations. Taken together, these defects contribute neither to the high prevalence of low HDL cholesterol levels in the population nor to the associated coronary risk. 7 Among those proteins that either constitute or process HDL, only apo A-IV and E are known to exhibit structural polymorphisms with frequent isoforms in Caucasian populations. The impact of these polymorphisms on the regulation of HDL cholesterol levels is controversial.
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Apo A-IV, as a component of chylomicrons, is secreted by enterocytes into lymphatic fluid. 1114 In fasting plasma, most of apo A-IV is associated with HDL.
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In vitro, apo A-IV activates LCAT, 17 -18 is involved in HDL remodeling, 19 modulates lipoprotein lipase activation through apo C-II, 20 and specifically interacts with HDL-binding sites on various cells, thereby promoting cholesterol efflux. chromosome II. 2 7 2 9 In Caucasian populations the apo A-IV gene exhibits four nonsynonymous polymorphisms in codons -8,127,347, and 360 and additional variation with rare mutant alleles. 9 ' 10 -3035 The histidine for glutamine replacement (Gln-»His) at position 360 of the mature protein can be detected by isoelectric focusing (IEF). 6 -30 Reported allele frequencies for the two isoforms, apo A-IV-1 (apo A-IV^ O bi) and apo A-FV-2 (apo A-IV^ m,), are .91 to .93 and .07 to .09, respectively. 3643 In some population studies, apo A-IV-1/2 heterozygotes exhibit significantly higher levels of HDL cholesterol 44 In two groups of probands we recently observed that apo A-IV (360: His) decreased lipoprotein(a) levels.
To obtain more detailed information of possible effects of the Gln-*His polymorphism in apo A-IV on HDL metabolism, we analyzed the impact of this substitution on the concentrations of HDL apolipoproteins and HDL subfractions as well as plasma activities of LCAT and CETP in coronary heart disease patients.
Methods Subjects
The electrophoretically detectable apo A-IV polymorphism was analyzed in 426 male and 188 female patients from a cardiac rehabilitation center who underwent coronary angiography because of symptoms of coronary heart disease. 45 Venous blood samples were drawn as early as 4 weeks after myocardial infarction or cardiac surgery and after overnight fasting. Serum was used for quantification of lipids, lipoproteins, and apolipoproteins and for determination of the apo A-IV polymorphism at codon 360 by IEF. EDTA-blood samples were immediately placed on ice to yield plasma for measurements of plasma lipid transfer activities. After centrifugation at 4°C for 15 minutes at 200Qg, sera and plasma samples were divided into aliquots and immediately frozen at -70°C.
Measurements of Lipids, Lipoproteins, and Apolipoproteins
Serum concentrations of triglycerides and cholesterol were quantified with an autoanalyzer (Hitachi/Boehringer). HDL cholesterol concentrations were measured after precipitation of apo B-containing lipoproteins with phosphotungstic acid/ MgCl 2 (Boehringer Mannheim). LDL cholesterol was calculated by using the Friedewald formula, 46 except when triglycerides were >400 mg/dL. Concentrations of apo A-I, apo A-II, and apo B were determined with a modified commercially available turbidimetric assay (Boehringer Mannheim). 47 Apo A-IV was quantified by electroimmunodiffusion and a rabbit anti-human apo A-IV antiserum. 48 The serum concentration of HDL containing apo A-I but not apo A-II (Lp A-I) was determined with a commercially available electroimmunodiffusion assay (Sebia).
Isolation of Apo A-I
Plasma activities of LCAT and CETP were determined by use of apo A-I-containing proteoliposomes as donors of pH]cholesterol and [ 3 H]cholesterol esters, respectively. For this purpose, apo A-I was isolated from plasma 49 by sequential ultracentrifugation of plasma lipoproteins, delipidation of HDL (1.063<rf<1.21 g/mL), and reversed-phase high-performance liquid chromatography of HDL apolipoproteins. Purity of apo A-I was ascertained by IEF and sodium dodecyl sulfate-polyacrylamide gel electrophoresis.
Determination of LCAT Activity in Exogenous Substrates
The activity of plasma to esterify radiolabeled cholesterol was determined by using either exogenous 50 or endogenous 51 substrates. LCAT activity on exogenous substrates has been shown to correlate with LCAT mass. 52 By contrast, esterification of radiolabeled cholesterol on endogenous substrates appears to reflect interaction between LCAT and various endogenous lipoproteins. 51 For the exogenous substrate assay (ie, LCAT activity), 10 /xg apo A-I was incorporated into liposomes that were prepared by the method of Batzri and Korn 53 and that contained 1 iiCi [ . Unesterified cholesterol and cholesterol esters in the lower phase were separated by thin-layer chromatography and counted for radioactivity. LCAT activity was calculated by multiplying the percentage of radiolabeled cholesterol esters produced per time by the concentration of unesterified cholesterol in the substrate. Every sample was determined in duplicate in a series of no more than 10 samples. The intra-assay coefficient of variation (CV) was 5% and the interassay CV 10%.
Determination of Cholesterol Esterification Rates in Endogenous Substrates
The endogenous substrate assay (ie, fractional esterification rate [FER] ) measured the activity of plasma (P-FER) 51 or apo B-free plasma (H-FER) 54 H]cholesterol in 3 jtL ethanol was dried on 5-mm filter paper plates that were subsequently incubated overnight at 4°C with 200 /xL plasma (for P-FER) or apo B-free plasma (for H-FER). Before and after subsequent incubation at 37°C, 50 /xL plasma was removed for incubation with 1 mL of 99% ethanol for lipid extraction. Unesterified cholesterol and cholesterol esters were separated by thin-layer chromatography so that their radioactivities could be counted separately. FER was calculated as the difference between the percentage of radiolabeled cholesterol esters before and after incubation at 37°C. All samples were measured in duplicate in series of no more than 10 samples. The intra-assay and interassay CVs for both assays ranged from 6% to 8% and from 11% to 14%, respectively.
Determination of CETP Activity CETP activity was determined as described by Kato et al 35 and Nakanishi et al. 56 In this assay, apo A-I-containing proteoliposomes were used as donors and LDL as acceptors of radiolabeled cholesterol esters. Proteoliposomes containing 3 mg apo A-I, 7 mg egg yolk lecithin, 1.16 mg unesterified cholesterol, 77.5 /xg cholesteryl oleate, and 10 ttCi [ sample on ice. LDL was then precipitated with 5 mmol/L MgCl 2 and dextran sulfate (weight ratio to LDL protein, 0.01). Radioactivity in the supernatant and infranatant was counted separately. CETP activity was calculated as the transferred cholesteryl oleate per time according to the percentage of the transferred label. All samples were measured in duplicate in series of no more than 10 samples. The intra-assay and interassay CVs amounted to 2% and 7%, respectively.
Phenotyping of Apo A-IV Polymorphism
The Gln->His polymorphism of apo A-IV at position 360 was analyzed as a phenotype by IEF of serum and subsequent immunoblotting. 3 *- 38 Immunodetection was performed with a rabbit anti-human apo A-IV antiserum, a biotinylated donkey anti-rabbit antiserum (Amersham), and streptavidin-horseradish peroxidase.
Statistical Analyses
Statistical analyses were done with SPSS. All parameters are adjusted for age, body mass index, diabetes mellitus, smoking status, and intake of lipid-lowering drugs and are presented as mean±SD except for Lp(a), triglycerides, and the ratio of LCAT activity to CETP activity. Because of their asymmetric frequency distributions, these parameters are expressed as geometric means and -1S<AT< + 1S confidence intervals as obtained by natural logarithm transformation. After adjustment, it was necessary to perform all statistical tests with parametric analyses (Student's t test, Pearson correlations). To estimate the proportional effect of the apo A-IV polymorphism on the variation in lipid metabolism, we performed a multiple regression analysis. Age, body mass index, intake of lipid-lowering drugs, smoking status, diabetes mellitus, and apo A-IV polymorphism were used as independent variables and the phenotypic measures as dependent variables. Regression analysis was performed first with the apo A-IV polymorphism and then without. Differences in R 2 values give the proportion of the variation that is accounted for by the apo A-IV polymorphism. Table 1 summarizes the data on lipid metabolism of 367 male and 167 female apo A-IV (360:Gln/Gln) homozygotes and 57 male and 19 female apo A-IV (360: Gin/His) heterozygotes. Only two male and two female homozygotes for apo A-IV (360: His/His) were identified, and because of this low number, were not considered in the statistical analysis ( Table 2 ). The apo A-IV (360: Gin/His) polymorphism had opposite effects in men compared with women in terms of all parameters of lipid metabolism except Lp(a), which was lower in apo A-IV-1/2 heterozygotes of both sexes compared with apo A-IV-1/1 homozygotes (Table 1) . Apo A-IV-1/2 was associated with lower mean levels of cholesterol, triglycerides, LDL cholesterol, and apo B in men but See the footnote to Table 1 for an explanation of abbreviations.
Results
by guest on April 13, 2017 http://atvb.ahajournals.org/ See the footnote to Table 1 for an explanation of same abbreviations. LCAT indicates lecithin:cholesterol acyttransferase; P-FER, fractional esterification rate in plasma; H-FER, fractional esterlflcation rate in HDL; and CETP, cholesteryl ester transfer protein.
Concentrations of tnglycerides and the ratio of LCAT to CETP in both men and women as well as CETP activity in women are presented as geometric means with ±1S confidence Intervals as calculated by natural logarithm transformation. Data are presented from a subgroup of patients presented in Table 1 . Data were corrected for age, Intake of lipid-lowering drugs, diabetes mellitus, and smoking.
•Activities of LCAT, FER, H-FER, and CETP were determined in 77 apo A-IV (360:Gln/Gln) homozygotes and 39 apo A-IV (360: Gin/His) heterozygotes.
tP<.05, +P<.01, Mann-Whitney U test.
with higher levels in women. In contrast, concentrations of HDL cholesterol, Lp A-I, and apo A-I were higher in male heterozygotes for apo A-IV-1/2 but lower in female heterozygotes. After adjustment for age, smoking status, diabetes mellitus, and intake of lipid-lowering drugs, only the differences in Lp A-I values between male apo A-IV-1/2 heterozygotes and apo A-IV-1/1 homozygotes remained significant (P<.05, Student's t test). In a multiple regression analysis we calculated the effect of apo A-IV polymorphism on Lp A-I serum concentrations after accounting for age, body mass index, diabetes mellitus, use of lipid-lowering drugs, and smoking status. The apo A-IV polymorphism contributed 1% of the variation in Lp A-I levels in this population.
To analyze in more detail the effect of the Gln->His polymorphism on apo A-IV in HDL metabolism in men, we randomly selected 38 male and 15 female apo A-IV-1/2 heterozygotes and 104 male and 15 female apo A-IV-1/1 homozygotes who were matched by age and measured the concentrations of apo A-IV and the activities of plasma lipid transfer enzymes (Table 3) . Also in these subgroups, the apo A-IV polymorphism exerted opposite effects on men and women in terms of serum concentrations of tnglycerides, HDL cholesterol, LDL cholesterol, Lp A-I, apo A-I, and apo B. In men the differences for Lp A-I were significant (P<.05). Mean serum concentrations of apo A-IV were higher in apo A-IV (360: Gin/His) heterozygotes of both sexes but only in men was this difference significant (P<.01, Student's t test). Furthermore, apo A-IV-1/2 heterozygotes of both sexes had significantly lower CETP activities (/><.O5, Student's t test). LCAT activity was oppositely affected by the apo A-IV polymorphism in men versus women, but the differences were significant only for men (P< .05, Student's / test). In the aforementioned multiple regression model, the apo A-IV polymorphism explained 3% to 4% of the variation in apo A-IV levels and 5% (men) to 18% (women) of the variation in CETP activity. Although opposite effects were seen in men and women, 6% to 7% of the variation in plasma LCAT activity was determined by the apo A-IV polymorphism.
In univariate regression analysis, we tested the relations of serum concentrations of apo A-IV and Lp A-I as well as plasma activities of LCAT and CETP to other variables of lipid metabolism. Table 4 summarizes the results of univariate Pearson regression analyses obtained in men and Table 5 the results obtained in women. In both sexes, as expected, Lp A-I had strongly positive correlations with HDL cholesterol and apo A-I and negative correlations with tnglycerides, which remained after multivariate regression analysis (not shown). In both sexes apo A-IV correlated positively with Lp A-I. In men this relation was highly significant and remained so after multivariate regression analysis. Furthermore, apo A-IV concentration correlated positively with HDL cholesterol, apo A-I, and apo A-II in men but not in women. In men, LCAT activity correlated positively with HDL cholesterol, Lp A-I, and apo A-IV and negatively with triglycerides and CETP activity. The correlations of LCAT activity with Lp A-I and triglycerides remained stable after multivariate regres- See the footnote to Tables 1 and 3 for an explanation of abbreviations.
n=113 for LCAT, CETP, H-FER, and fractional esterification rate in plasma (P-FER); n=152 for apo A-IV; n=1025 for Lp A-l. *P<.05, tP<.01, *P<.001. No significant correlation coefficient was found for P-FER. sion analysis. In women the correlations of LCAT with HDL cholesterol, Lp A-I, and apo A-I had the same trend but were insignificant because of the low number of individuals analyzed. In men but not in women, CETP activity correlated negatively with LCAT activity. See the footnote to Tables 1 and 3 for an explanation of abbreviations.
n=30 for LCAT, CETP, FER-HDL, and fractional esterification rate in plasma (P-FER); n=22 for apo A-IV; n=186 for Lp A-I. *P<.05, tP<.001.
Discussion
Previous physicochemical and metabolic studies have revealed considerable differences between the two structural isoforms apo A-IV (360: Gin) and apo A-IV (360: His). The latter binds with higher affinity to phospholipid vesicles 58 and differs in its LCAT-activating properties. 33 -38 Moreover, in HDL the fractional catabolic rate of apo A-IV-2 is decreased compared with that of apo A-IV-1. 59 In contrast to these experimental data, previous population studies have yielded controversial results on the effect of the Gln->His polymorphism at residue 360 of apo A-IV on lipoprotein metabolism. Its effect on HDL cholesterol concentration has been a matter of particular debate. 3744 In this study of patients with coronary heart disease, we found that serum concentrations of triglycerides, HDL cholesterol, LDL cholesterol, Lp A-I, apo A-I, and apo B are oppositely affected by the apo A-IV polymorphism in men versus women. Analogous observations on the sex-specific effect of the apo A-IV polymorphism have been made in two recent studies of normolipidemic Germans and Hispanics.
3443 Except for Lp A-I levels in men, the differences in concentrations of lipids, lipoproteins, and apolipoproteins are not significant between apo A-IV (360:Gln/Gln) homozygotes and apo A-IV (360: Gin-»His) heterozygotes. Moreover, in a multiple regression model that also considered other well-known influences on lipid metabolism, the apo A-IV (Gin/His) polymorphism contributed 1% at most to the variation of these parameters, including LpA-I in men, in the population.
Standard parameters of lipoprotein metabolism, such as triglycerides or HDL cholesterol, are the final result of complex processes that are regulated by apolipoproteins, enzymes, and receptors. Therefore, the conflicting results of various studies on the importance of the apo A-IV polymorphism for lipoprotein metabolism together with our finding of sex-related differences suggest that any effect of the apo A-IV (360: Gin/His) polymorphism on HDL cholesterol levels is modulated by other factors, including sex, disease, or other genetic polymorphisms.
To understand in more detail the possible role of the apo A-IV polymorphism on lipoprotein metabolism in vivo, we investigated its association with parameters that are functionally related to apo A-IV, namely serum concentration of apo A-IV and plasma activities of LCAT and CETP. In both sexes, heterozygosity for apo A-IV (360: Gin/His) was associated with a higher serum concentration of apo A-IV and lower activity of CETP. Moreover, the apo A-IV polymorphism contributed considerably to the variation in these parameters compared with its negligible contribution to the variation in HDL cholesterol or Lp A-I. Since apo A-IV dissociates very easily from lipoproteins, 15 higher concentrations of apo A-IV in apo A-IV (360: Gin/His) heterozygotes may indicate a higher affinity of apo A-IV (360: His) for phospholipids because of its higher hydrophobicity and a-helix content. 58 The higher affinity of apo A-IV (360: His) to HDL may even be enhanced by the lower activity of CETP in the plasma of apo A-IV-1/2 heterozygotes, since in vitro the binding of apo A-IV to HDL is increased by inhibition of CETP. 60 The higher LCAT activity in plasma of male apo A-IV (360: Gin/ His) heterozygotes may also stabilize binding of apo A-IV to HDL, since in vitro the inhibition of LCAT prevents the association of apo A-IV with HDL.
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Whereas it is well known that CETP contributes to the distribution of apo A-IV among various lipoproteins, 60 it is not clear how the apo A-IV polymorphism may influence CETP activity in plasma. One possibility is that the apo A-IV polymorphism influences the residence time of CETP-containing particles in plasma. Alternatively, as a component of chylomicrons and a modulator of lipoprotein lipase activity, apo A-IV may influence postprandial hyperlipidemia and thereby CETP gene expression. 63 Also, the different LCAT activities in plasma of apo A-IV (360:Gln/Gln) homozygotes and apo A-IV (360: Gin/His) heterozygotes are difficult to explain. Because of the opposite associations in men and women, it is unlikely that differences in LCAT activation by apo A-IV isoforms are responsible. 33 ' 58 Moreover, apo A-I activates LCAT more efficiently than does apo A-IV 1864 and is present in plasma at concentrations that exceed those of apo A-IV by several fold. Because LCAT activity as measured in exogenous substrates reflects LCAT mass 52 and because LCAT is associated with distinct HDL subclasses, 166567 it is more likely that the apo A-IV polymorphism determines the serum concentration of LCAT-containing particles whose identity has yet to be defined.
In conclusion, the association of apo A-IV-1/1 and apo A-IV-1/2 with significantly different serum concentrations of apo A-IV, plasma activities of lipid transfer enzymes, and serum levels of HDL subfractions indicates that the Gln-*His polymorphism at residue 360 of apo A-IV influences HDL metabolism. The opposite effects on parameters of lipid metabolism in men and women as well as the small variation exerted by this polymorphism on lipids and lipoproteins compared with the higher variation exerted on apo A-IV levels and lipid transfer enzyme activities point to the importance of other modulating factors, including gender. In men, the association of the apo A-IV (360: His) allele with higher LCAT activity, lower CETP activity, and higher concentrations of Lp A-I indicates a positive role of this polymorphism for reverse cholesterol transport and coronary risk. Some reduced coronary risk is also expected in view of the lower serum concentration of Lp(a) associated with apo A-IV-1/2 heterozygosity (References 34 and 45 and Table 1 ). The allele frequency of apo A-IV-2 observed in this study of coronary heart disease patients, however, did not differ from that observed in a recent study of healthy students from the same geographic region (.069 versus .070 34 ). Although insignificant, the mean age of male patients at their first myocardial infarction differed by approximately 2 years. This difference may indirectly indicate some antiatherogenic effects of the apo A-IV-2 allele. However, this effect does not appear to be large or to affect life expectancy, since in a recent study of octogenarians we did not observe an increased frequency of apo A-IV-2 alleles in the elder generation.
